Evidence map›Paper›PMID 36581817›Full record

ArticleBMC cancer2022

Metabolic abnormalities and survival among patients with non-metastatic breast cancer.

Alexa S Zimbalist, Bette J Caan, Wendy Y Chen, Elizabeth A Mittendorf, Deborah A R Dillon, Charles Quesenberry, Elizabeth M Cespedes Feliciano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Alexa S ZimbalistDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA.
Bette J CaanDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA.
Wendy Y ChenChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Elizabeth A MittendorfDivision of Breast Surgery, Brigham and Women's Hospital, Boston, MA, 02215, USA.
Deborah A R DillonHarvard Medical School, Boston, MA, 02215, USA.
Charles QuesenberryDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA.
Elizabeth M Cespedes FelicianoDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, 5Th Floor, Oakland, CA, 94612, USA. elizabeth.m.cespedes@kp.org.
Kaiser Permanente · USBrigham and Women's Hospital · USDana-Farber Brigham Cancer Center · USHarvard University · US

Funding

Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors - Disparities SupplementR01CA251589 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI FELICIANO, ELIZABETH MARJORIE CESPEDES · 2020 to 2025
$3.5M
NCI NIH HHS R01 CA251589
6 · The paper itself

Abstract

backgroundResearch on the impact of metabolic abnormalities on breast cancer prognosis is limited by small samples and assessment of laboratory values at a single time point, often prior to cancer diagnosis and treatment. In this population-based cohort, time-updated laboratory values were adjusted for cancer treatment to assess the association between metabolic risk factors (glucose, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides) and breast cancer survival.

methods13,434 women diagnosed with stage I-III breast cancer from 2005-15 at Kaiser Permanente were included. All outpatient fasting glucose, HDL-C, LDL-C, and triglyceride values from diagnosis through 2019 or death were extracted from electronic medical records. Risk of breast cancer-specific mortality was evaluated with Cox proportional hazards models adjusted for metabolic labs, demographics, body mass index, diabetes, dyslipidemia and anti-hypertensive medications, tumor characteristics (stage, ER and HER2 receptor status) and cancer treatment (use of chemotherapy, tamoxifen, and aromatase inhibitors).

resultsMean (SD) age at diagnosis was 62.3 (11.8) years. Over a median follow-up of 8.6 years, 2,876 patients died; 1,080 of breast cancer. Patients with low HDL-C (≤ 45 vs. > 45 mg/dL) had higher breast cancer-specific mortality (HR, 1.77; 95% CI, 1.53-2.05), as did those with elevated fasting glucose (> 99 vs. 60-99 mg/dL) (HR, 1.19; 95% CI, 1.03-1.37). Elevated levels of triglycerides and LDL-C were not associated with breast cancer-specific mortality.

conclusionsHigh fasting glucose and low HDL-C evaluated over time after cancer diagnosis were associated with higher breast cancer mortality independent of cancer treatments and changes in other metabolic risk factors. Future studies should address whether pharmacologic or lifestyle treatment of glucose and lipids after breast cancer diagnosis can optimize survival outcomes.

Indexed as

Breast NeoplasmsDiabetes MellitusCholesterol, HDLCholesterol, LDLFemaleGlucoseHumansMiddle AgedRisk FactorsTriglyceridesCholesterol, HDLCholesterol, LDLGlucoseTriglyceridesBreast cancerBreast cancer survivalDyslipidemiaHyperglycemiaMetabolic dysregulationPrognosis

Identifiers

PMID36581817
PMCPMC9801571
OpenAlexW4313261556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.